Symptomatic pleural effusion in adult liver transplant candidates: prevalence, disease severity and post-transplant mortality Authors: Ilker Kolbas, Adem Tuncer, Emrah Sahin, Abuzer Dirican Published: 2025 ABSTRACT AbstractBackgroundSymptomatic pleural effusion in patients with decompensated cirrhosis—often termed hepatic hydrothorax—is thought to reflect advanced disease and may carry poor prognosis. However, its impact on outcomes after liver transplantation remains uncertain.MethodsIn this retrospective cohort study, we evaluated all adult patients who underwent their first liver transplantation at a single tertiary centre between 2015 and 2022. Baseline demographics, clinical characteristics and disease severity scores were extracted from institutional databases. The presence of symptomatic pleural effusion requiring therapeutic intervention was determined from imaging reports and clinical records. Multivariable logistic regression was used to assess associations between pleural effusion and mortality at 30 days, 90 days and overall, adjusting for age, sex, Model for End-Stage Liver Disease (MELD) score and ascites.ResultsOf 459 transplant candidates, 59 (12.8%) had symptomatic pleural effusion. These patients displayed higher MELD scores and a greater prevalence of ascites compared with those without effusion, though age and sex distributions were similar. Unadjusted mortality rates were higher in the effusion group (20.3%, 28.8% and 33.9% at 30 days, 90 days and overall, respectively), but in multivariable analyses pleural effusion was not an independent predictor of mortality at any time point. MELD score showed a borderline association with early mortality.ConclusionsSymptomatic pleural effusion is common among liver transplant candidates and is associated with more advanced liver disease, yet it does not independently increase post-transplant mortality. These findings suggest that pleural effusion should prompt careful optimisation of ascites and early transplant evaluation but need not preclude transplantation. Future studies should explore effusion characteristics and management strategies to better stratify risk.Keywords: Liver transplantation, Symptomatic pleural effusion, Hepatic hydrothorax, MELD score, Mortality Introduction End-stage liver disease (ESLD) remains a major cause of mortality worldwide, and cirrhosis was the ninth leading cause of death for men in the United States in 2016 [1]. Liver transplantation (LT) is the only definitive therapy for advanced hepatic failure; it restores normal health, improves quality of life and extends survival by roughly 15 years [2]. Despite improvements in surgical technique and immunosuppression, organ shortage and careful candidate selection remain critical challenges [3]. Candidates are prioritized using prognostic models such as the Model for End-Stage Liver Disease (MELD) score, which estimates three-month mortality and guides organ allocation [4]. However, these scores do not fully capture the impact of certain complications, including refractory ascites and pleural effusions. Accumulation of transudative pleural fluid without primary cardiopulmonary disease, known as hepatic hydrothorax (HH), occurs when ascitic fluid traverses small diaphragmatic defects into the pleural cavity [5–7]. HH is reported in approximately 5–16% of patients with decompensated cirrhosis and accounts for roughly 2% of all pleural effusions [6]. The pathophysiology involves portal hypertension, salt and water retention and negative intrathoracic pressure that favor one-way transfer of ascitic fluid; as a result, pleural effusions develop predominantly on the right side (85%) [6, 8]. Patients with HH generally have advanced liver disease and high MELD and Child–Pugh scores [5]. Untreated HH carries a poor prognosis, with median survival of only 8–12 months and mortality risk higher than that associated with refractory ascites [9]. Studies have shown that refractory HH is an independent predictor of death and that HH is associated with increased rates of sepsis, acute kidney injury and spontaneous bacterial pleuritis [10]. LT is the definitive management for refractory HH because it addresses portal hypertension and corrects the underlying hepatic dysfunction [11]. However, the effect of pre-transplant symptomatic pleural effusion on post-transplant outcomes is not fully understood. Only a small proportion of patients with HH receive MELD exception points to increase their priority on transplant lists [12]. Evidence suggests that patients with refractory HH who receive MELD exceptions have improved post-transplant survival compared with matched controls [13]. Nevertheless, earlier studies focusing on HH primarily evaluated pre-transplant mortality; those that considered post-transplant outcomes often analysed large registry data and did not include detailed clinical characteristics such as ascites, drainage interventions or symptomatic burden [14]. Consequently, the prognostic value of symptomatic pleural effusions identified during transplant evaluation remains uncertain. The present retrospective cohort study was conducted to explore the clinical significance of symptomatic pleural effusion in adult liver transplant candidates at a single tertiary centre. Our objectives were to (i) determine the prevalence of symptomatic pleural effusion among transplant candidates, (ii) compare demographic and disease-severity characteristics between patients with and without pleural effusion and (iii) examine the association of pre-transplant pleural effusion with 30-day, 90-day and overall post-transplant mortality. We hypothesized that patients with symptomatic pleural effusion would exhibit more severe liver disease, have higher ascites rates and MELD scores, and experience worse short-term mortality compared with those without effusion. Materials and methods Study design and participants We performed a retrospective cohort study of adult liver transplant candidates evaluated at a tertiary university hospital. The institutional transplant registry was queried for all individuals aged ≥ 18 years who underwent their first liver transplant between January 2015 and December 2022. Patients were excluded if they had multi-organ transplants (simultaneous liver–kidney transplant), paediatric transplantation, repeat transplantation or missing key variables. A total of 459 candidates met the inclusion criteria. Of these, 59 patients (12.8%) had symptomatic pleural effusion documented on pre-operative imaging or clinical assessment. This study was conducted in accordance with the Declaration of Helsinki and approved by the institutional ethics committee; the need for individual informed consent was waived because the study used de-identified retrospective data. Data collection and definitions Demographic and clinical variables were extracted from the transplant registry and electronic medical records. These included age at transplant, sex, body mass index, primary liver disease aetiology, and presence of ascites. Disease-severity scores were collected: the MELD score and MELD-Na were calculated as described by Biggins and colleagues [15]; the Child–Pugh score was derived from bilirubin, albumin, prothrombin time, ascites and encephalopathy [16]. Symptomatic pleural effusion was defined as a pleural effusion in a patient with decompensated cirrhosis that caused respiratory symptoms (dyspnoea, chest discomfort or hypoxaemia) and required therapeutic intervention (thoracentesis, pigtail catheter insertion or chest tube placement) prior to or during the transplant hospitalization. In line with our institutional practice, effusions were classified as hepatic hydrothorax when they occurred in the context of portal hypertension and ascites, without evidence of an alternative primary cause on routine pre-transplant evaluation. Specifically, patients with pleural effusions that were adjudicated in the medical record as cardiogenic (due to systolic or diastolic heart failure), infectious (parapneumonic effusion or empyema), malignant or related to pulmonary embolism were not coded as having symptomatic pleural effusion for this study and were therefore excluded from the pleural effusion group. The presence of ascites was noted from imaging and clinical records and was considered supportive of a hepatic origin of the effusion. In this retrospective dataset, symptom status was determined from contemporaneous clinician documentation at the time of imaging and/or pleural intervention. Respiratory symptoms were considered attributable to pleural effusion when the treating team documented a clinical association between the effusion and dyspnoea, chest discomfort, and/or hypoxemia in proximity to the imaging report and prior to intervention. To reduce etiologic misclassification, we reviewed available pre-transplant evaluation notes and admission records for alternative primary causes of pleural effusion. Effusions were not classified as hepatic hydrothorax–related symptomatic pleural effusion when the record identified another dominant etiology (cardiogenic effusion/heart failure exacerbation or pleural infection/parapneumonic effusion/empyema) as the primary explanation. Outcome variables were 30-day, 90-day and overall mortality following transplantation. Mortality status and dates of death were obtained from hospital records and confirmed via national death registries. Patients were followed until death or the date of last registry update (27 April 2025), whichever came first. Statistical analysis Continuous variables were summarized as mean ± standard deviation (SD) or median and interquartile range (IQR) depending on distribution. Normality was assessed using the Shapiro–Wilk test. Between-group comparisons for continuous variables were performed using independent-samples t-tests when data were normally distributed; otherwise, the Mann–Whitney U test was applied. Categorical variables were compared using the chi-square test or Fisher’s exact test when expected cell counts were < 5. Logistic regression models were constructed to evaluate the association between symptomatic pleural effusion and mortality at 30 days, 90 days and overall, adjusting for age, sex, MELD score and presence of ascites. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. For descriptive mortality proportions, we additionally report 95% confidence intervals to communicate precision of estimates. Statistical significance was set at p < .05. Analyses were conducted using SPSS version 26 (IBM Corp., Armonk, NY, USA). In addition, time-to-event analyses were performed. Overall survival time was defined as the number of days from the date of liver transplantation to death or censoring at the last follow-up date (27 April 2025). Kaplan–Meier survival curves were generated for patients with and without symptomatic pleural effusion and compared using the log-rank test. Cox proportional hazards regression models were then fitted to estimate hazard ratios (HRs) and 95% CIs for the association between symptomatic pleural effusion and mortality, adjusting for age, sex, MELD score and presence of ascites. For the Cox analysis, cases with missing MELD or age data were excluded. Proportional hazards assumptions were checked using graphical diagnostics and found to be acceptable. Sample size considerations Because this was a retrospective observational study that included all eligible transplant recipients during the specified period, no formal sample size calculation was performed. Nevertheless, to ensure adequate model stability in logistic regression, we verified that the number of outcome events exceeded ten per covariate included in the multivariate models, consistent with published recommendations. Results Out of 459 liver transplant candidates included in the study, 59 patients (12.8%) had a symptomatic pleural effusiondocumented prior to transplantation. Table 1 presents the baseline demographic and clinical characteristics of patients with and without pleural effusion. Patients with pleural effusion showed more advanced liver disease severity compared to those without effusion. Notably, ascites was present in 76.3% of the pleural effusion group versus 40.5% of the no-effusion group (p < .001). The mean MELD score was also higher among patients with pleural effusion (20.1 vs. 17.1, p = .01). There were no significant differences in age or sex distribution between the two groups (p = .09 and p = .43, respectively). Additionally, a substantial proportion of the pleural effusion patients required therapeutic intervention for fluid management. In fact, one-third of patients with pleural effusion (20 out of 59) underwent pleural fluid drainage either before or during the transplant hospitalization. Specifically, 8 patients (13.6%) underwent a preoperative thoracentesis or pigtail catheter placement for pleural fluid, another 8 (13.6%) had pleural fluid drained intraoperatively at the time of transplant, and 3 patients (5.1%) required a chest tube in the early postoperative period to manage recurrent effusions. The remaining cases of effusion were managed conservatively without invasive drainage. Table 1Baseline characteristics of liver transplant candidates with and without pleural effusionCharacteristicNo Pleural Effusion (n = 400)Pleural Effusion (n = 59)p-valueAge, years, mean (SD)44.7 (14.5)48.8 (15.0)0.09BMI (kg/m²), mean ± SD29.4 ± 4.926.6 ± 4.60.047Etiology of Liver Disease, n (%) Viral Hepatitis (HBV, HCV, HDV)5 (8.5%)180 (45.0%) NASH / Metabolic4 (6.8%)60 (15.0%) Alcohol-Associated2 (3.4%)80 (20.0%) Cryptogenic6 (10.2%)40 (10.0%) Autoimmune / Cholestatic1 (1.7%)30 (7.5%) Other1 (1.7%)10 (2.5%)Male sex, n (%)236 (59.0%)31 (52.5%)0.43Ascites present, n (%)162 (40.5%)45 (76.3%)0.001MELD score, mean (SD)17.1 (7.0)20.1 (8.2)0.01Continuous variables are presented as mean (SD) and were compared by independent-samples t-tests. Categorical variables were compared by chi-square testsMELD Model for End-Stage Liver Disease, SD Standard deviation Baseline characteristics of liver transplant candidates with and without pleural effusion Continuous variables are presented as mean (SD) and were compared by independent-samples t-tests. Categorical variables were compared by chi-square tests MELD Model for End-Stage Liver Disease, SD Standard deviation As shown in Table 1, the presence of pleural effusion was strongly associated with the presence of ascites and higher MELD scores. Approximately three-quarters of patients with pleural effusion had coexisting ascites, a rate nearly double that of patients without effusion. The mean MELD score in the effusion group was about 3 points higher than in the no-effusion group. These differences were statistically significant (p < .05). By contrast, there was no significant difference in mean age between the groups (on average about 49 and 45 years, p = .09), nor in sex distribution (the proportion of male patients was ~ 53% in the effusion group vs. ~ 59% in the non-effusion group, p = .43). It is also noteworthy that one in every three patients with a pleural effusion required an invasive intervention to drain the fluid either before or during the transplant. Table 2 summarizes post-transplant survival outcomes in patients with and without pleural effusion. Although mortality rates were consistently higher in the pleural effusion group at all time points examined, these differences did not reach statistical significance. In the early post-transplant period, 30-day mortality was 20.3% for patients with pleural effusion compared to 16.0% for those without effusion (p = .40). By 90 days, nearly 29% of the pleural effusion group had died, versus about 20% of the no-effusion group (p = .11). Overall mortality by the end of the follow-up period was 33.9% in the effusion group, compared to 24.5% in the non-effusion group (p = .12). Thus, there was a trend toward worse survival in patients who had a symptomatic pleural effusion, with roughly one-third not surviving to one year post-transplant, compared to about one-quarter of those without an effusion. However, the sample size was limited (only 59 patients with effusion), and the observed differences did not achieve statistical significance at the conventional 0.05 level. In other words, the presence of a symptomatic pleural effusion was associated with a higher mortality rate in absolute terms, but this study did not find definitive evidence that pleural effusion was an independent predictor of post-transplant mortality. Table 2Post-transplant mortality outcomes by presence of symptomatic pleural effusionOutcomeNo Pleural Effusion (n = 400)Pleural Effusion (n = 59)p-value30-day mortality, n (%)64 (16.0%)12 (20.3%)0.4090-day mortality, n (%)79 (19.8%)17 (28.8%)0.11Overall mortality, n (%)98 (24.5%)20 (33.9%)0.12Mortality values represent the number (percentage) of patients who died by the given time point after transplantation. Overall mortality includes all deaths that occurred during the total follow-up period (up to approximately 2 years post-transplant) Post-transplant mortality outcomes by presence of symptomatic pleural effusion Mortality values represent the number (percentage) of patients who died by the given time point after transplantation. Overall mortality includes all deaths that occurred during the total follow-up period (up to approximately 2 years post-transplant) Additional analysis adjusting for liver disease severity (MELD and ascites) indicated that pleural effusion on its own was not an independent risk factor for mortality once those factors were accounted for. Overall, while patients with symptomatic pleural effusions tended to have worse outcomes, the difference was not statistically confirmed in this cohort. To investigate whether symptomatic pleural effusion was an independent predictor of early or overall mortality after liver transplantation, we performed multivariable logistic regression models including pleural effusion (yes/no), age, sex, MELD score and presence of ascites. Logistic regression is appropriate for binary outcomes and allows simultaneous adjustment for multiple confounders. The results are summarized in Table 3. These multivariable analyses indicate that symptomatic pleural effusion was not an independent predictor of mortality at 30 days, 90 days or overall follow-up once age, sex, MELD score and presence of ascites were accounted for. Although patients with pleural effusion had higher unadjusted mortality rates, the adjusted odds ratios were modest in magnitude (OR ≈ 1.5–1.7 across all outcomes) and their confidence intervals included unity, resulting in non-significant p-values (p > .10 for each model). Age, sex and ascites were also not significantly associated with mortality in these models. MELD score showed a borderline association with 30-day mortality (OR 1.03 per point increase; p = .056) but no significant association with 90-day or overall mortality. Table 3Multivariable logistic regression models for 30-day, 90-day and overall mortality after liver transplantation (N = 459)Variable30-day OR (95% CI)30-day p90-day OR (95% CI)90-day pOverall OR (95% CI)Overall pPleural effusion (Yes vs. No)1.69 (0.87–3.30)0.1221.66 (0.88–3.12)0.1181.48 (0.80–2.75)0.210Age (per year)1.00 (0.98–1.02)0.9180.99 (0.98–1.01)0.2931.01 (0.99–1.02)0.505Male sex (vs. Female)0.93 (0.57–1.53)0.7850.75 (0.47–1.19)0.2220.96 (0.62–1.50)0.873MELD score (per point)1.03 (1.00–1.07)0.0561.00 (0.96–1.03)0.8160.99 (0.96–1.02)0.519Ascites (Yes vs. No)1.07 (0.65–1.77)0.7851.14 (0.71–1.82)0.5831.03 (0.66–1.61)0.886 Multivariable logistic regression models for 30-day, 90-day and overall mortality after liver transplantation (N = 459) We next examined post-transplant survival using time-to-event methods. Kaplan–Meier survival curves for patients with and without symptomatic pleural effusion. Survival probabilities were consistently lower in the effusion group, particularly during the first post-transplant year, but the difference between groups was not statistically significant (log-rank χ² = 2.40, p = .12). The estimated 30-day, 90-day and 1-year survival rates were 79.7%, 71.2% and 65.5% in patients with symptomatic pleural effusion, compared with 84.3%, 80.2% and 76.8% in those without effusion. In the Cox proportional hazards model including 431 patients with complete data, symptomatic pleural effusion was not associated with a significantly increased hazard of death after adjustment for age, sex, MELD score and ascites (HR 1.02, 95% CI 0.61–1.72, p = .93; Table 4). By contrast, higher MELD score (HR 1.05 per point, 95% CI 1.02–1.07, p = .001) and the presence of ascites (HR 1.53, 95% CI 1.01–2.30, p = .04) were independently associated with worse survival, whereas age and sex were not significant predictors. Table 4Cox proportional hazards model for overall survival after liver transplantationPredictorHazard ratio95% CIp valueSymptomatic pleural effusion1.020.61–1.720.93Age (per year)1.000.99–1.010.62Male sex0.830.57–1.210.32MELD (per point)1.051.02–1.070.001Ascites1.531.01–2.300.04 Cox proportional hazards model for overall survival after liver transplantation To explore whether major postoperative complications might account for the observed mortality patterns, we performed a descriptive comparison of severe infections, renal failure and other major complications between patients with and without symptomatic pleural effusion. Infectious complications were infrequent and occurred only in the no-effusion group (0/59 [0.0%] and 8/400 [2.0%], p = .60). Renal complications were also rare (1/59 [1.7%] and 3/400 [0.8%], p = .42). Overall, any major postoperative complication was documented in 13.6% of patients with effusion and 14.3% of those without effusion (p > .99; Table 5). These events therefore did not cluster in the pleural effusion group and are unlikely to explain the lack of an independent association between effusion and post-transplant mortality. Table 5Major postoperative complications according to presence of symptomatic pleural effusionComplication typeWith symptomatic pleural effusion (n = 59)Without symptomatic pleural effusion (n = 400)p valueInfectious complications0 (0.0%)8 (2.0%)0.60Renal complications1 (1.7%)3 (0.8%)0.42Any major complication8 (13.6%)57 (14.3%)0.99 Major postoperative complications according to presence of symptomatic pleural effusion Discussion The present study examined 459 liver transplant candidates and found that 59 (12.8%) had symptomatic pleural effusions. Patients with effusions were older but not significantly so, and the sex distribution was comparable between groups. As expected, those with effusions had more advanced liver disease, evidenced by higher MELD scores and a greater prevalence of ascites compared with patients without effusions. Mortality rates at 30 days, 90 days and overall were numerically higher among patients with symptomatic pleural effusion, but after adjusting for age, sex, MELD score and ascites, the effusion was not an independent predictor of death in any time frame [17]. Importantly, the pleural effusions included in our analysis were clinically adjudicated as complications of advanced cirrhosis rather than primary cardiopulmonary disease. All effusion cases occurred in candidates undergoing transplant evaluation for ESLD, and none had an alternative diagnosis such as decompensated heart failure, pneumonia, pulmonary embolism or malignant pleural disease recorded as the primary cause of the effusion at baseline. In this discussion we compare these findings with recent literature from 2024 to 2025 and consider the clinical implications. In clinical practice, symptomatic pleural effusion in patients with advanced cirrhosis is most often considered within the spectrum of hepatic hydrothorax, reflecting severe portal hypertension and impaired sodium–water homeostasis. Contemporary practice guidance emphasizes that liver transplantation is the definitive therapy, whereas bridging strategies typically include optimization of salt restriction/diuretics and intermittent therapeutic thoracentesis; in carefully selected patients with refractory hydrothorax, TIPS may be considered as a bridge while balancing the risks of encephalopathy and other complications. In contrast, prolonged chest tube drainage is generally discouraged because of substantial risks including infection, renal dysfunction, electrolyte/protein losses, and clinical deterioration. Against this background, our finding that pleural effusion was not independently associated with post-transplant mortality after adjustment supports the interpretation that pleural effusion primarily behaves as a marker of advanced disease severity rather than an autonomous driver of adverse post-transplant outcomes [18]. Symptomatic pleural effusion complicated nearly 13% of transplant candidates in our cohort. This prevalence sits within the broader epidemiologic range reported for hepatic hydrothorax in decompensated cirrhosis, which is estimated to occur in 5–16% of patients with advanced liver disease [19]. The majority of hepatic hydrothoraces are right-sided due to the proximity of the liver and the relative friability of the right hemidiaphragm [10]. Our study did not specifically record laterality, but nearly all symptomatic effusions requiring drainage in cirrhotic patients occur on the right side, suggesting that most of our cases were likely hepatic hydrothorax rather than effusions from cardiopulmonary causes. In keeping with prior studies, patients with pleural effusions in our cohort had more severe portal hypertension, as evidenced by higher MELD scores and more frequent ascites; the review by Ismail et al. notes that hydrothorax is seen more frequently in patients with higher MELD and Child–Pugh scores and lower albumin levels [20]. Ascites, present in over three-quarters of our effusion patients, is a prerequisite for hydrothorax formation and reflects the unidirectional flow of ascitic fluid into the pleural space through diaphragmatic defects [21]. Hepatic hydrothorax results from a combination of portal hypertension, sodium and water retention and structural defects in the diaphragm that allow ascitic fluid to pass into the pleural cavity [22]. The pathogenesis differs from cardiogenic or malignant effusions because the pleural fluid originates from the peritoneal cavity rather than the systemic circulation. In our cohort, the strong association between effusion and higher MELD scores suggests that symptomatic pleural effusion is a marker of advanced liver dysfunction rather than an independent pathologic process. This aligns with literature showing that patients with hydrothorax have higher MELD and Child–Pugh scores and more frequent renal dysfunction [23]. The presence of spontaneous bacterial pleuritis in up to 5–15% of hydrothorax cases adds to the morbidity of these patients, with an episode mortality approaching 20% [24]. Although our dataset did not record pleural fluid infections, clinicians should recognise that any symptomatic pleural effusion in cirrhosis warrants evaluation for infection. Unadjusted mortality in our cohort was higher among patients with symptomatic pleural effusions, but logistic regression adjusting for age, sex, MELD score and ascites demonstrated that the effusion itself did not significantly increase mortality. This finding contrasts with studies in the general cirrhotic population where hepatic hydrothorax is described as an independent predictor of death and is associated with a median survival of only 8–12 months [25]. For example, a retrospective cohort of patients with hydrothorax reported mortality rates of 10%, 26% and 57% at 30 days, 90 days and one year, respectively. Our mortality rates (20.3%, 28.8% and 33.9% at the same time points) were similar or slightly higher but did not reach statistical significance after adjusting for MELD score, suggesting that disease severity, not the effusion itself, drives mortality. This interpretation is supported by recent analyses of national transplant databases: Fathma et al. (2024) found that awarding MELD exception points for hydrothorax decreased post-transplant mortality (OR 0.60) and that baseline MELD score remained the primary predictor of death [22]. Moreover, prospective cohort studies comparing transplant outcomes in patients with and without hydrothorax report no differences in postoperative ventilation, sepsis, early mortality or long-term survival [26]. These findings mirror our observation that, after controlling for liver disease severity, symptomatic pleural effusion does not independently worsen post-transplant outcomes. The borderline significance of MELD score in our logistic model underscores its central role in prognostication; each additional point increased 30-day mortality risk by 3%, consistent with established scoring systems [26]. Approximately one-third of our patients with symptomatic pleural effusion required invasive drainage before or during transplantation. While therapeutic thoracentesis provides rapid symptom relief, repeated procedures carry risks of pneumothorax and infection, and indwelling pleural catheters or chest tubes have been associated with high mortality. A Taiwanese population-based study reported a 12-month mortality rate approaching 90% after chest tube insertion for hepatic hydrothorax and found higher 30-day mortality compared with thoracentesis (23.5% vs. 18.6%) [27]. Consequently, current guidelines recommend avoiding intercostal chest tubes for hydrothorax management, reserving them only for emergencies such as severe respiratory distress or concomitant empyema [25]. Transjugular intrahepatic portosystemic shunt (TIPS) provides a bridge to transplant by reducing portal hypertension and has been shown to improve survival in refractory hydrothorax [28]. Ultimately, liver transplantation remains the definitive treatment; recent studies demonstrate that post-transplant survival is similar or even better in patients with hydrothorax compared with those transplanted for other indications [19]. Our results support these recommendations: effusion was not an independent predictor of post-transplant mortality, highlighting that controlling underlying portal hypertension and proceeding to transplantation rather than focusing solely on pleural drainage is crucial. Clinicians should therefore prioritise optimisation of ascites management and timely transplant referral for patients with symptomatic pleural effusion. Several limitations warrant consideration. First, the study’s retrospective design is subject to confounding and missing data. We were unable to calculate survival time or hazard ratios because follow-up durations were not uniformly recorded; thus, our mortality analysis relied on dichotomous outcomes at 30 and 90 days and overall. Second, the sample of patients with symptomatic pleural effusion was relatively small (n = 59), limiting statistical power to detect subtle effects. Third, although all effusions were classified as hepatic hydrothorax based on their occurrence in patients with decompensated cirrhosis and the absence of a documented cardiogenic, infectious or malignant cause in the pre-transplant work-up, we did not have uniform pleural fluid biochemical data or detailed echocardiographic parameters for every case. Some residual misclassifications between hepatic hydrothorax and other transudative effusions is therefore possible; however, the strong association with ascites and higher MELD scores in the effusion group suggests that the large majority of effusions were indeed related to portal hypertension. Fourth, we lacked detailed data on the size of effusions, laterality, number of drainage procedures and use of TIPS, precluding analysis of these factors. Finally, our single-centre cohort may not be generalisable to other transplant centres or to patients with compensated cirrhosis. In summary, symptomatic pleural effusion in liver transplant candidates is a marker of advanced portal hypertension, manifesting alongside high MELD scores and ascites. Although unadjusted mortality was higher among patients with effusion, multivariable analysis showed no independent effect on 30-day, 90-day or overall mortality [29]. These findings align with recent literature indicating that liver disease severity, rather than pleural effusion itself, drives post-transplant outcomes [10]. Clinicians should therefore focus on optimising ascites management, avoiding chest tubes, considering TIPS as a bridge and expediting transplant evaluation. Future studies with larger cohorts and prospective design should explore the impact of effusion characteristics (volume, side, recurrence) and interventions (TIPS vs. catheter) on outcomes. Investigating the immunologic and hemodynamic changes associated with pleural effusion may further elucidate mechanisms linking portal hypertension to pulmonary complications. Ultimately, our results suggest that symptomatic pleural effusion should prompt aggressive management of the underlying cirrhosis and early consideration of transplantation but should not by itself deter transplant candidacy. Time-to-event analyses were then performed. Kaplan–Meier curves were compared using the log-rank test, and adjusted Cox proportional hazards regression results are presented in Table 4. Collectively, these findings suggest that while symptomatic pleural effusions signal more advanced liver disease in transplant candidates, their presence alone does not independently increase post-transplant mortality when established risk factors are taken into account. This interpretation aligns with the principle that multivariable logistic regression evaluates the independent effect of each predictor after controlling for confounders. Acknowledgements The authors acknowledge their responsibility for ensuring the accuracy and integrity of the study and compliance with ethical standards. We are grateful to the staff of the Liver Transplant Unit and the Division of Hepatology at Istanbul Aydin University Medical Park Florya Hospital for their exceptional clinical care and assistance with data collection. We also thank the patients and their families for their trust and participation. This work was carried out without specific funding; the authors report no conflicts of interest. The study was performed in accordance with the ethical standards of the Institutional Review Board of 104–2025 and with the 1964 Helsinki declaration and its later amendments. Clinical trial registration We confirm that our study is not a clinical trial. “Clinical trial number: not applicable.” Using AI ChatGPT was used for language editing only. The content and overall flow of the manuscript were entirely developed by the authors.” Authors’ contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Ilker Kolbas, Adem Tuncer, Emrah Sahin and Abuzer Dirican. The first draft of the manuscript was written by Ilker Kolbas and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Funding “The authors received no financial support for the research, authorship, and/or publicationof this article.” Data availability De-identified data and analysis code are available from the corresponding author upon reasonable request and subject to institutional policies. Declarations Ethics approval and consent to participate Approved by the Istanbul Aydin University Medical Park Florya Hospital IRB (Approval No. 104/2025); informed consent was waived due to retrospective design. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement De-identified data and analysis code are available from the corresponding author upon reasonable request and subject to institutional policies.